Business Wire

NEDGROUP-INVESTMENTS

10.5.2023 09:50:27 CEST | Business Wire | Press release

Share
Nedgroup Investments expands boutique advantage range, onboards David Roberts and Alex Ralph to launch fixed income boutique

Nedgroup Investments, a global asset manager with over $20bn AUM, is launching an in-house multi-boutique platform which will feature a growing range of active investment strategies characterised by deep alignment of client and fund manager interests.

Tom Caddick, Managing Director of Nedgroup Investments (International) commented: “It's harder for boutiques to set up now because of the onerous regulatory requirements and the difficulty of raising sufficient capital. We want to facilitate start-up boutiques to better serve the needs of our clients and provide a wider range of investment opportunity. We can create a more diverse fund management sector for the benefit of the end investor. I’m thrilled to launch our innovative structure with two conviction managers I have known and respected for over 20 years.”

Fixed-income veterans David Roberts and Alex Ralph will run an active global bond fund as the first launch of these in-house managed strategies.

Roberts commented: “I have returned to active investing because market conditions are too compelling to ignore. I have always had conviction to invest when risk and reward are in the client’s favour. After a couple of years when return expectations were negative, we are back in an environment where fixed income is once again a diversifier, a very attractive alternative to equities. The old normal.”

Ralph adds: “Many have been waiting a decade for this type of entry point and the possibility of earning significant, long term positive returns without the need to venture into the dark, equity-like corners of the bond market.”

Addressing the attractions of the firm, Roberts commented: “Nedgroup Investment’s has a long-standing belief in the benefits to investors of boutique models and they share my client-centric approach. Those were the deciding factors for me. It is rare these days to find a business willing to innovate and support a boutique from inception.”

Apiramy Jeyarajah, who joined Nedgroup Investments as Chief Commercial Officer in April 2023, added: “Starting an investment boutique is increasingly difficult. We are excited to offer clients access to compelling teams, complementing the existing boutiques on our platform. Nurturing opportunities with experienced fund managers will help investors benefit from increased choice and a competitive edge.”

About Nedgroup Investments

Nedgroup Investments is a global asset manager with over $20 billion AUM with its international business led from London and global headquarters in Cape Town. Nedgroup Investments is known for its award winning ‘Best of Breed’ partnership model with leading boutique managers in London, Los Angeles, New York and Sydney, offering investors access to the world’s best managers and their funds.

The Nedgroup Investments Boutique Advantage Philosophy

Nedgroup Investments’ fundamental belief is that the best performing investment funds are run by managers that are autonomous, focused and have a concentrated alignment of interests with the unit-holders of their fund.

Fund Range

Nedgroup Investments has two fund ranges – Nedgroup Investments Funds Plc (launched in November 2008) and Nedgroup Investments Multifunds Plc (launched in August 2011).

About David Roberts

David Roberts is a fixed income investor with over 30 years’ experience. He is known for his skin in the game investment style and was previously head of fixed income at Liontrust until early 2022. Previously, he was a fund manager with Aegon Asset Management (formerly Kames Capital) where he was also co-head of fixed income and worked for 14 years. Prior to that, he held roles at Britannia Investment Managers and Lloyds Bank.

About Alex Ralph

Alex Ralph is a highly respected fixed-income fund manager with over two decades of experience in the industry. She is widely recognized for her strong track record of success and is considered one of the leading fixed-income investors of her generation. Alex was most recently a partner at Artemis Investment Management where she helped set up the bond desk launching the Strategic bond fund in 2005. In 2014, she was also appointed lead fund manager on the Artemis high income fund. The desk managed some £3 billion in credit by the end of her tenure at Artemis. Alex holds a BSc in Economics from London School of Economics and is a CFA Charter holder.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230509006145/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release

Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to

Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release

About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,

AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release

Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break

Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release

Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti

Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release

Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye